Present possibilities of therapies for gout
More details
Hide details
Online publication date: 2009-06-10
Reumatologia 2009;47(2):75-81
Treatment of acute gouty arthritis, intercritical gout and tophaceous gout is presented as well as management in asymptomatic hyperuricemia.
Keenan RT, O’Brien WR, Crettenden DR, et al. Gout management in a primary care setting: evidence for possible suboptimal treatment. ACR/ARHP Scientific Meeting, 08, program book supplement, 11. .
Roubenoff R. Gout and hyperuricemia. Rheum Dis Clin North Am 1990; 16: 539-550. .
Singh G, Dabbous O, Vadhavkar S, et al. Not only a swollen big toe: increasing all-cause hospitalizations in patients with gout in the United States: 1988-2005. Ann Rheum Dis 2008; (67 Suppl II); 96-97. .
Annemans L, Spaepen E, Gaskin M, et al. Gout in the UK and Germany: prevalence comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67: 960-966. .
Symmons D, Turher G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 2002; 41: 793-800. .
Mikuls TR, Farrar JT, Bilker WD, et al. Gout epidemiology: results from the UK General Pracice Database, 1990-1999. Ann Rheum Dis 2005; 64: 267-272. .
Riedel AA, Nelson M, Wallace K, et al. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10: 308-314. .
Wortmann RL. Management of hyperuricemia. Arthritis and Allied Conditions. A Textbook of Rheumatology. Koopmann WJ (ed.), 13th ed. Williams & Wilkins, Baltimore 1996; 2073-2081. .
Wortmann RL, Kelley WN. Gout and hyperuricemia. Kelley’s Textbook of Rheumatology. Harris ED, Budd RC, Firestein GS, Genovese MC, Sergent JS, Ruddy S, Slegde CB (eds), 7th ed. Elsevier Saunders, Philadelphia 2005; 1402-1429. .
Choi HK. Dietary risk factors for rheumatic diseases. Curr Opin Rheumatol 2005; 17: 141-146. .
Choi HK, Atkinson K, Karlson EW, et al. Alcohol intake and risk of incident gout in men: a prospective study. Lancet 2004; 363: 1277-1281. .
Choi HK, Mount DB, Reginato AM; Pathogenesis of gout. Ann Intern Med 2005; 143: 499-516. .
Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521. .
Netea MG, Kullberg BJ, Blok WL, et al. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood 1997; 89: 577-582. .
Patterson RA, Horsley ET, Leake DS. Prooxidant and antioxidant properties of human serum ultrafiltrates toward LDL: important role of uric acid. J Lipid Res 2003; 44: 512-521. .
Khosla UM, Zharikov S, Finch JL, et al. Hyperuricemia induces endothelial dysfunction. Kidney Int 2205; 67: 1739-1742. .
Lippi G, Montagnana M, Franchina M, et al. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008; 392: 1-7. .
Burack DA, Griffith BP, Thompson ME, Kahl LE. Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med 1992; 92: 141-146. .
Kittleson MM, Bead V, Fradley M, et al. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. J Heart Lung Transplant 2007; 26: 498-503. .
Zhang W, Doherty M, Pasqual E, et al. EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1301-1311 (także: Medycyna Praktyczna 2007; 6: wydanie specjalne – 6/2007; 39-48). .
Schlesinger N, Norquist JM, Boice JA, Watson DJ. Serum urate during acute gouty arthritis attacks. Ann Rheum Dis 2008; 67 (Suppl II): 97. .
European Society of Hypertension – European Society of Cardiology. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053. .
Caliskan M, Erdogan D, Gullu H, et al. Association between serum uric acid levels and coronary flow reserve in hypertensive patients without concomitant risk factors. Blood Press 2006; 16: 254-261. .
Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH. Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 2005; 45: 18-20. .
Schachter M. Uric acid and hypertension. Curr Pharm Des 2005; 11: 4139-4143. .
Verdecchia P, Schillaci G, Reboldi G, et al. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 2000; 36: 1072-1078. .
Madsen TE, Muhlenstein JB, Carlquist JF, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 2005; 25: 45-49. .
Niskanen LK, Laksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med 2004; 164: 1546-1551. .
Strasak A, Ruttmann E, Brant L, et al. VHM&PP Study Group. Serum uric acid and risk of cardiovascular mortality, a prospective long-term study of 83683 Austrian men. Clin Chem 2008; 54: 273-284. .
Fang J, Alderman MH. Serum uric acid and cardiovascular mortality in the NHANES 1 epidemiologic follow-up study. 1971-1992. National Health and Nutrition Examination Survey. JAMA 2000; 293: 2404-2410. .
Mazza, Pesina AC, Pavei A, et al. Predictors of stroke mortality in elderly people from the general population. The Cardiovascular Study in the Elderly. Eur J Epidemiol 2001; 17: 1097-1104. .
Milinis HJ, Kalantzi KJ, Goudevenos JA, et al. Serum uric acid levels and risk for acute ischaemic non-embolic stroke in elderly subjects. J Intern Med 2005; 258: 435-441. .
Schretlen DJ, Inscore AB, Yannorsdall TD, et al. Serum uric acid and brain ischemia in normal elderly adults. Neurology 2007; 69: 1418-1423. .
Choi HK, Ford ES, Li S, Curhan G. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007; 57: 109-115. .
Puig JG, Martinez MA. Hyperuricemia, gout and the metabolic syndrome. Curr Opin Rheumatol 2008; 20: 187-191. .
Yoo TW, Sung KC, Shin HS, et al. Relationship between serum uric acid concentration and insulin resistance and metabolic syndrome. Circ J 2005; 69: 928-933. .
Doehner W, Schoene, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002; 105: 2619-2624. .
Perez-Ruiz F, Schlesinger N. Management of gout. Scand J Rheumatol 2008; 37: 81-89. .
Zhang W, Doherty M, Bardin J, et al. EULAR evidence based recommendations for gout. Part II. Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-1324 (także: Medycyna Praktyczna 2007/6; wydanie specjalne, 39-48). .
Morris I, Varughese G, Mattingly P. Colchicine in acute gout. Br Med J 2003; 327: 1275-1276. .
Terkeltaub R, Furst DE, Bennett K, et al. Low dose (1.8 mg) vs high dose (4.8 mg) oral colchicine regimens in patients with acute gout flare in a large, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Arthritis Rheum 2008; 58 (Suppl): 879-880. .
Simkin PA, Gardner GC. Colchicine use in cyclosporine treated transplant recipiens: how little is too much? J Rheumatol 2000; 27: 1334-1337. .
Fernandez C, Noguera R, Gonzales JA, Pasqual E. Treatment of acute attacks of gout with small doses of intraarticular tiramcinolone acetonide. J Rheumatol 1999; 26: 2285-2286. .
Taylor CT, Brooks NC, Kelley KW. Corticotropin for acute management of gout. Ann Pharmacother 2006; 35: 365-368. .
Petersel D, Schlesinger N. Treatment of acute gout in hospitalized patients. J Rheumatol 2007; 34: 1566-1568. .
Jordan KM, Cameron JS, Snaith M, et al. British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007; 46: 1327-1374. .
Perez-Ruiz F, Calabozo M, Pijoan JI, et al. Effects of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 2002; 47: 356-360. .
Becker MA, Schumacher HR JR, Wortmann RL, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005; 353: 2450-2461. .
Pasqual E, Sivera F. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66: 1056-1058. .
Shoji A, Yamanaka H, Kamatani N. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321-325. .
Becker M, Schumacher HR. Jr, Espinosa L, et al. A phase 3 randomised, controlled, multicenter, double-blind trial (RCT) comparing efficacy and safety of daily Febuxostat (FEB) and Allopurinol (ALLO) in subjects with gout. ACR/ARHP Scientific Meeting, 08 program book supplement, 57. .
Whelton A, MacDonald P, Lloyd E, Lademacher C. Beneficial relationship of serum urate (sUA) reduction and estimated glomerular filtration rate (eGFR) improvement/maintenance in hyperuricemic gout subjects treated for up to 5.5 years with Febuxostat (FEB). ACR/ARHP Scientific Meeting 08, program book supplement, 3. .
Becker MA, Treadwell EL, Baraf HS, et al. Immunoreactivity and clinical response to pegloticase (PGL): pooled data from GOUT1 and GOUT2, PGL phase 3 randomised, double blind, placebo-controlled trials. Arthritis Rheum 2008; 58 (Suppl): S880. .
Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia. Adv Drug Deliv Rev 2008; 60: 59-68. .
Sundy JS, Baraf HS, Becker MA, et al. Efficacy and safety of intravenous (IV) Pegloticase (PGL) in subjects with treatment failure gout (TFG): Phase 3 results from GOUT1 and GOUT2. Arthritis Rheum 2008; 58 (Suppl): S400-401. .
Reinders MK, Haagsma O, Van Roon EN, et al. Dose-escalation of allopurinol versus benzbromarone in gout patients: a randomised controlled trial. Ann Rheum Dis 2008; 67 (Suppl II): 98. .
Feher MD, Hepburn AL, Hogarth MB, et al. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricemia and gout. Rheumatology 2003; 42: 321-325. .
Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002; 20: 347. .
Sundy J, Terkeltaub R, Schumacher HR, et al. Placebo-controlled pilot study of rilonacept (IL-1 TRAP), a long acting IL-1 inhibitor, in refractory chronic active gouty arthritis. Ann Rheum Dis 2008; 67 (Suppl II): 97. .
Cheney W, Larson G, Lai Ch, et al. MEK inhibitor RDEA119 supresses inflammatory cytokine production induced by monosodium urate crystals. Arthritis Rheum 2008; 58 (Suppl): S879. .
Underwood M. Diagnosis and management of gout. Br Med J 2006; 332: 1315-1319. .
Wortmann RL. The management of gout: it should be crystal clear. J Rheumatol 2006; 33: 1921-1922. .
Pasqual E, Sivera T. Why is gout so poorly managed? Ann Rheum Dis 2007; 66: 1269-1270. .
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Journals System - logo
Scroll to top